225 related articles for article (PubMed ID: 19447868)
1. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Hanrahan EO; Ryan AJ; Mann H; Kennedy SJ; Langmuir P; Natale RB; Herbst RS; Johnson BE; Heymach JV
Clin Cancer Res; 2009 May; 15(10):3600-9. PubMed ID: 19447868
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Heymach JV; Paz-Ares L; De Braud F; Sebastian M; Stewart DJ; Eberhardt WE; Ranade AA; Cohen G; Trigo JM; Sandler AB; Bonomi PD; Herbst RS; Krebs AD; Vasselli J; Johnson BE
J Clin Oncol; 2008 Nov; 26(33):5407-15. PubMed ID: 18936474
[TBL] [Abstract][Full Text] [Related]
4. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Herbst RS; Sun Y; Eberhardt WE; Germonpré P; Saijo N; Zhou C; Wang J; Li L; Kabbinavar F; Ichinose Y; Qin S; Zhang L; Biesma B; Heymach JV; Langmuir P; Kennedy SJ; Tada H; Johnson BE
Lancet Oncol; 2010 Jul; 11(7):619-26. PubMed ID: 20570559
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO; Heymach JV
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Natale RB; Bodkin D; Govindan R; Sleckman BG; Rizvi NA; Capó A; Germonpré P; Eberhardt WE; Stockman PK; Kennedy SJ; Ranson M
J Clin Oncol; 2009 May; 27(15):2523-9. PubMed ID: 19332730
[TBL] [Abstract][Full Text] [Related]
7. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
8. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Heymach JV; Lockwood SJ; Herbst RS; Johnson BE; Ryan AJ
Ann Oncol; 2014 Oct; 25(10):1941-1948. PubMed ID: 25057173
[TBL] [Abstract][Full Text] [Related]
9. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Heymach JV; Johnson BE; Prager D; Csada E; Roubec J; Pesek M; Spásová I; Belani CP; Bodrogi I; Gadgeel S; Kennedy SJ; Hou J; Herbst RS
J Clin Oncol; 2007 Sep; 25(27):4270-7. PubMed ID: 17878479
[TBL] [Abstract][Full Text] [Related]
10. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
[TBL] [Abstract][Full Text] [Related]
11. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Shi Y; Song Y
Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):e7-e15. PubMed ID: 23177099
[TBL] [Abstract][Full Text] [Related]
14. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
Qi WX; Tang LN; He AN; Shen Z; Yao Y
Lung; 2011 Dec; 189(6):437-43. PubMed ID: 21986852
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Tsao AS; Liu S; Lee JJ; Alden CM; Blumenschein GR; Herbst R; Davis SE; Kim E; Lippman S; Heymach J; Tran H; Tang X; Wistuba I; Hong WK
J Thorac Oncol; 2013 May; 8(5):658-61. PubMed ID: 23584298
[TBL] [Abstract][Full Text] [Related]
16. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
de Boer RH; Arrieta Ó; Yang CH; Gottfried M; Chan V; Raats J; de Marinis F; Abratt RP; Wolf J; Blackhall FH; Langmuir P; Milenkova T; Read J; Vansteenkiste JF
J Clin Oncol; 2011 Mar; 29(8):1067-74. PubMed ID: 21282537
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Morabito A; Piccirillo MC; Costanzo R; Sandomenico C; Carillio G; Daniele G; Giordano P; Bryce J; Carotenuto P; La Rocca A; Di Maio M; Normanno N; Rocco G; Perrone F
Drugs Today (Barc); 2010 Sep; 46(9):683-98. PubMed ID: 20967300
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang X; Qin Y; Li H; Bai C; Zhu T; Xu J; Wu C; Wu M; Wang C; Song H; Wei L; He J
Asian Pac J Cancer Prev; 2011; 12(11):2857-63. PubMed ID: 22393954
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
